Hosted on MSN3d
Bispecific antibody startup Bambusa raises $90m to fund clinical trials
Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...
The American Journal of Managed Care1d
Banner Year for Bispecifics as Therapies Advance Into the Community Setting
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Bispecific Antibody Market Expands with Over 600 Clinical Trials – New Patent Analysis Report Released
Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...
FierceBiotech6d
Boston biotech Bambusa banks $90M for next-gen bispecifics
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...
Contract Pharma1d
Celonic Group, LINDIS Biotech Sign Manufacturing Service Agreement for Catumaxomab
Celonic Group, a “Pure Play” biologics contract development and manufacturing organization (CDMO), has signed a multi-year ...
BioSpace6d
I&I Startup Bambusa Nabs $90M for Bispecific Antibodies
The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...
Healio3d
Regimen may become new standard for relapsed/refractory diffuse large B-cell lymphoma
The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...
Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer
Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation ...
Context Therapeutics to Participate in Upcoming Investor Conferences
Context will also participate in one-on-one meetings at each of the above conferences.